HOSP Forms to Advocate for Integrated Specialty Pharmacies

As the specialty pharmacy industry continues to grow, more entities within the health care system are boosting their capabilities in this area, and various health systems are implementing some form of a specialty pharmacy. These entities have some issues and challenges that may differ from those of traditional specialty pharmacies. In order to make sure their voices are heard, a group of seven health systems plus a specialty pharmacy integrator have joined together to form a new alliance known as the Health System Owned Specialty Pharmacy Alliance (HOSP).

In an Aug. 18 blog on his Drug Channels website, Adam Fein, Ph.D., CEO of Drug Channels Institute, a subsidiary of Pembroke Consulting, Inc., shared information from the American Society of Hospital Pharmacists’ survey of 487 pharmacy practices located in hospitals. That survey found that 26% of respondent hospitals in 2019 owned a specialty pharmacy, up from 20% in 2018 and less than 9% in 2015.

Angela Maas

Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy (formerly called Specialty Pharmacy News) since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at HemAware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/10/WordPress-Featured-Image-radar-on-specialty-pharmacy-FDA-Extends-Xeljanz-Safety-Warnings-to-Other-JAK-Inhibitors.jpg
October 14

FDA Extends Xeljanz Safety Warnings to Other JAK Inhibitors

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2021/09/WordPress-Featured_FDA-Requires-Warnings-on-Labels-of-JAK-Inhibitors-for-Inflammatory-Conditions.jpg
October 14

FDA Approves Byooviz, First Ophthalmology Biosimilar in U.S.

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2021/10/WordPress-Featured-Image-radar-on-specialty-pharmacy-Groups-Warn-Against-Avastin-Biosimilar-Off-Label-Use-in-Eyes.jpg
October 14

Groups Warn Against Avastin Biosimilar Off-Label Use in Eyes

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today